Diagnostic delay and access to care in bronchiectasis: data from the EMBARC/ELF patient survey

Abstract

Bronchiectasis is receiving increased awareness from clinicians, researchers, and stakeholders. However, despite the development of international and national guidelines in bronchiectasis, clinical practice does not necessarily follow quality standards and clinical recommendations. The European Multicenter Bronchiectasis Audit and Research Collaboration (EMBARC) together with the European Lung Foundation (ELF) coordinate patient-initiated activities designed to facilitate bronchiectasis awareness and care [1]. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of Interest: A. Spinou has nothing to disclose. Conflict of Interest: M. Almagro has nothing to disclose. Conflict of Interest: B. Harris is a patient with bronchiectasis and a member of the ELF Bronchiectasis Patient Advisory Group. This is an unpaid, voluntary role. Conflict of Interest: J. Boyd has nothing to disclose. Conflict of Interest: T. Berg has nothing to disclose. Conflict of Interest: B. Herrero-Cortina reports payment or honoraria for lectures, presentations, manuscript writing or educational events from SEPAR (Spanish Respiratory Society). Conflict of Interest: A. Posthumous is a patient with bronchiectasis and a member of the ELF Bronchiectasis Patient Advisory Group. This is an unpaid, voluntary role. Conflict of Interest: S. Aliberti has nothing to disclose. Conflict of Interest: B. Crossley is a voluntary member of the European Lung Foundation's Patient Advisory Group, for bronchiectasis. Conflict of Interest: T.F. Ruddy has nothing to disclose. Conflict of Interest: N. Stein has nothing to disclose. Conflict of Interest: M.L. Crichton reports consultancy fees from Boxer Capital LLC, Conflict of Interest: P.C. Goeminne has nothing to disclose. Conflict of Interest: J.D. Chalmers has nothing to disclose. Conflict of Interest: M. Shteinberg reports grants from GSK, Novartis, writing fees from Bohringer Ingelheim, personal fees from GSK, Novartis, AstraZeneca, Kamada, Teva, GSK, Zambon, Airphysio, Bonus Biogroup, Syncrony medical, non-financial support from GSK, Boehringer Ingelheim, Actelion, GSK, Rafa.